AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38749594 — intervention group
Group type: COMPARATOR
Intervention: Stent-Preferred (SP) strategy
Number of subjects: 120
Study 38749592 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prasugrel (3.75 mg/d) monotherapy
Number of subjects: 1230
Study 38749592 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) with low-dose prasugrel and aspirin
Number of subjects: 1230
Study 38749682 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to environmental tobacco smoke (ETS)
Number of subjects: 735
Study 38749682 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive or minimally invasive biospecimens collection (saliva, buccal cells, dried blood spots, urine)
Number of subjects: 735
Study 38749682 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported and objective measures of ETS exposure
Number of subjects: 735
Study 38749692 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physical activity levels (measured using the International Physical Activity Questionnaire)
Number of subjects: 204
Study 38749694 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics for CRSwNP
Number of subjects: 0
Study 38749694 — intervention group
Group type: COMPARATOR
Intervention: Nasal corticosteroids, systemic corticosteroids, and surgery
Number of subjects: 0
Study 38749786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (measured by peak oxygen uptake, VO2)
Number of subjects: 0
Study 38750012 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training in patients with type 2 diabetes
Number of subjects: 59
Study 38750012 — intervention group
Group type: COMPARATOR
Intervention: Deconditioning in athletes
Number of subjects: 59
Study 38750012 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 59
Study 38750034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibisatamab alone in S1
Number of subjects: 377
Study 38750034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibisatamab with atezolizumab in S2
Number of subjects: 377
Study 38750034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibisatamab with obinutuzumab in S1
Number of subjects: 377
Study 38750102 — intervention group
Group type: EXPERIMENTAL
Intervention: NSupple (without silymarin)
Number of subjects: 0
Study 38750102 — intervention group
Group type: EXPERIMENTAL
Intervention: NSupple_Silybum (with silymarin)
Number of subjects: 0
Study 38750142 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-omics model
Number of subjects: 2457
Study 38750142 — intervention group
Group type: COMPARATOR
Intervention: Agatston score
Number of subjects: 2457
Study 38750162 — intervention group
Group type: EXPERIMENTAL
Intervention: diet plus phytosterol (2.6 g in 2 doses, with meals)
Number of subjects: 23
Study 38750162 — intervention group
Group type: COMPARATOR
Intervention: diet
Number of subjects: 23
Study 38750351 — intervention group
Group type: EXPERIMENTAL
Intervention: Senaparib 100 mg orally once daily for up to 2 years
Number of subjects: 404
Study 38750351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 38750375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene training (OHt) with toothbrush and dental floss
Number of subjects: 75
Study 38750375 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush alone
Number of subjects: 75
Study 38750386 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 6-month (PP6M)
Number of subjects: 0
Study 38750386 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone Palmitate 3-month (PP3M)
Number of subjects: 0
Study 38750398 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose analogue PET agent
Number of subjects: 0
Study 38750416 — intervention group
Group type: EXPERIMENTAL
Intervention: Health mediation (HM) intervention
Number of subjects: 726
Study 38750416 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 726
Study 38750487 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable tracheal stents
Number of subjects: 47
Study 38750518 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy with post-isometric relaxation exercises (Group B)
Number of subjects: 46
Study 38750518 — intervention group
Group type: COMPARATOR
Intervention: Massage therapy alone (Group A)
Number of subjects: 46
Study 38750557 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased psychosocial focus during children's developmental assessments
Number of subjects: 12
Study 38750557 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' initiatives to address psychosocial challenges
Number of subjects: 12
Study 38750557 — intervention group
Group type: EXPERIMENTAL
Intervention: Open communication style and trustful relationship
Number of subjects: 12
Study 38750557 — intervention group
Group type: EXPERIMENTAL
Intervention: Short consultation time, concerns about information use, stigma
Number of subjects: 12
Study 38750557 — intervention group
Group type: EXPERIMENTAL
Intervention: Enquiry about family's psychosocial circumstances
Number of subjects: 12
Study 38750557 — intervention group
Group type: EXPERIMENTAL
Intervention: Alignment of clinical and parental expectations
Number of subjects: 12
Study 38750562 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat version of the Longshi Scale
Number of subjects: 115
Study 38750562 — intervention group
Group type: COMPARATOR
Intervention: Paper-based version of the Longshi Scale
Number of subjects: 115
Study 38750572 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 1887
Study 38750572 — intervention group
Group type: COMPARATOR
Intervention: No statin use
Number of subjects: 1887
Study 38750572 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiated statin use during follow-up
Number of subjects: 1887
Study 38750590 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up intervention approach (IG-1)
Number of subjects: 16
Study 38750590 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-based intervention (IG-2)
Number of subjects: 16
Study 38750590 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led intervention (IG-3)
Number of subjects: 16
Study 38750590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 38750621 — intervention group
Group type: EXPERIMENTAL
Intervention: Colovac device (CD)
Number of subjects: 342
Study 38750621 — intervention group
Group type: COMPARATOR
Intervention: Diverting loop ileostomy
Number of subjects: 342
Study 38750712 — intervention group
Group type: EXPERIMENTAL
Intervention: G78717 fee-for-service physician payment for enhanced discharge planning
Number of subjects: 161328
Study 38750712 — intervention group
Group type: COMPARATOR
Intervention: No financial incentive (G78717-unexposed)
Number of subjects: 161328
Study 38750866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 772
Study 38750866 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 772
Study 38750866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 772
Study 38750866 — intervention group
Group type: COMPARATOR
Intervention: Vonoprazan 10 mg vs Placebo
Number of subjects: 772
Study 38750866 — intervention group
Group type: COMPARATOR
Intervention: Vonoprazan 20 mg vs Placebo
Number of subjects: 772
Study 38750866 — intervention group
Group type: EXPERIMENTAL
Intervention: All study arms (including both doses of vonoprazan and placebo)
Number of subjects: 772
Study 38750870 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg intravenously at baseline, then 90 mg subcutaneously every 8 weeks)
Number of subjects: 22
Study 38750950 — intervention group
Group type: EXPERIMENTAL
Intervention: Glow! Group Prenatal Care and Support (Glow/GC)
Number of subjects: 0
Study 38750950 — intervention group
Group type: COMPARATOR
Intervention: Enhanced individual prenatal care through the California Department of Public Health's Comprehensive Perinatal Services Program (CPSP/IC)
Number of subjects: 0
Study 38751081 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative predictors including self-reported central sensitisation, lower KOA grade, preoperative satisfaction, higher glycated haemoglobin, number of pain locations, and personal control
Number of subjects: 223
Study 38751362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotiglipron (180 mg/day)
Number of subjects: 100
Study 38751362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38751442 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg)
Number of subjects: 0
Study 38751442 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2)
Number of subjects: 0
Study 38751488 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 200
Study 38751488 — intervention group
Group type: COMPARATOR
Intervention: lapatinib plus capecitabine
Number of subjects: 200
Study 38751523 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab (15 mg/kg over at least 120 minutes) plus chemotherapy
Number of subjects: 123
Study 38751523 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (6 mg/kg over at least 30 minutes) plus chemotherapy
Number of subjects: 123
Study 38751579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashtanga Vinyasa Yoga Supta Method (AVYSM) - 12 weeks, two weekly one-hour yoga sessions
Number of subjects: 0
Study 38751579 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group - 12 weeks, protocolized course classes
Number of subjects: 0
Study 38751852 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial platelet-rich plasma (PRP) injection
Number of subjects: 92
Study 38751852 — intervention group
Group type: COMPARATOR
Intervention: Enthesis needling
Number of subjects: 92
Study 38752013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract (1000 mg/day)
Number of subjects: 25
Study 38752311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapartum azithromycin (2 g)
Number of subjects: 0
Study 38752311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38752352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg TID
Number of subjects: 385
Study 38752352 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 5 mg TID
Number of subjects: 385
Study 38752352 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg TID
Number of subjects: 385
Study 38752402 — intervention group
Group type: EXPERIMENTAL
Intervention: MW031
Number of subjects: 448
Study 38752402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 38752418 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days
Number of subjects: 200
Study 38752418 — intervention group
Group type: COMPARATOR
Intervention: No therapy for 31 days
Number of subjects: 200
Study 38752431 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CIVI) of Ketamine, starting at .05 mg/kg/hour and increased to .5 mg/kg/hour as needed over 5 days.
Number of subjects: 20
Study 38752557 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention
Number of subjects: 330
Study 38752577 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF PDGFRβ protein levels
Number of subjects: 36
Study 38752592 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-dose abrocitinib (200 mg)
Number of subjects: 0
Study 38752592 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose abrocitinib (100 mg)
Number of subjects: 0
Study 38752592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38752653 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Bowel Disorder (FBD)
Number of subjects: 452
Study 38752653 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of FBD at baseline
Number of subjects: 452
Study 38752650 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment to lower systolic blood pressure (target range, 130 to 140 mm Hg)
Number of subjects: 2404
Study 38752650 — intervention group
Group type: COMPARATOR
Intervention: Usual blood-pressure management (usual-care group)
Number of subjects: 2404
Study 38752650 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital blood-pressure reduction in hemorrhagic stroke patients
Number of subjects: 2404
Study 38752650 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital blood-pressure reduction in cerebral ischemia patients
Number of subjects: 2404
Study 38752802 — intervention group
Group type: EXPERIMENTAL
Intervention: pentavalent vaccine (DTwP-HB-Hib)
Number of subjects: 0
Study 38752802 — intervention group
Group type: EXPERIMENTAL
Intervention: hexavalent vaccine (DTaP-IPV-HB-Hib)
Number of subjects: 0
Study 38752902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure balloon occlusion (PCI)
Number of subjects: 51
Study 38752902 — intervention group
Group type: COMPARATOR
Intervention: Placebo inflation
Number of subjects: 51
Study 38752951 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-QCPHA features (including fractional flow reserve across the lesion, plaque burden, total plaque volume, low-attenuation plaque volume, and averaged percent total myocardial blood flow)
Number of subjects: 351
Study 38752951 — intervention group
Group type: COMPARATOR
Intervention: Reference model (Coronary Artery Disease Reporting and Data System and high-risk plaque)
Number of subjects: 351
Study 38752961 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravascular ICD
Number of subjects: 299
Study 38752963 — intervention group
Group type: EXPERIMENTAL
Intervention: PolarX cryoballoon
Number of subjects: 201
Study 38752963 — intervention group
Group type: COMPARATOR
Intervention: Arctic Front cryoballoon
Number of subjects: 201
Study 38752970 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular resistance reserve (MRR) <3.0 (CMD)
Number of subjects: 210
Study 38752970 — intervention group
Group type: EXPERIMENTAL
Intervention: MRR
Number of subjects: 210
Study 38752970 — intervention group
Group type: EXPERIMENTAL
Intervention: CFR, IMR, MRR
Number of subjects: 210
Study 38752972 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided intervention in nonculprit vessels (n = 320 nonculprit vessels)
Number of subjects: 1445
Study 38752972 — intervention group
Group type: COMPARATOR
Intervention: Culprit-only treatment (n = 903 nonculprit vessels from 685 patients)
Number of subjects: 1445
Study 38753093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT) with 5-ALA HCl, single 200 J/cm
Number of subjects: 10
Study 38753174 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental β-carotene (15 mg)
Number of subjects: 7
Study 38753174 — intervention group
Group type: EXPERIMENTAL
Intervention: Caco-2 cell model
Number of subjects: 7
Study 38753174 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat dairy-based meal
Number of subjects: 7
Study 38753174 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal matrix
Number of subjects: 7
Study 38753273 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 116
Study 38753273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 38753330 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral self-help intervention
Number of subjects: 154
Study 38753331 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) with Standard Care (SC)
Number of subjects: 206
Study 38753331 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) at NICU and postdischarge Music Therapy (MT)
Number of subjects: 206
Study 38753331 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) at both NICU and postdischarge
Number of subjects: 206
Study 38753374 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant monotherapy
Number of subjects: 1944
Study 38753415 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized 12-week health education program targeting an active lifestyle after oncology treatments.
Number of subjects: 150
Study 38753416 — intervention group
Group type: EXPERIMENTAL
Intervention: PREMIUM-CE item bank
Number of subjects: 498
Study 38753416 — intervention group
Group type: EXPERIMENTAL
Intervention: PREMIUM-CE scores
Number of subjects: 498
Study 38753416 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT simulations
Number of subjects: 498
Study 38753448 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 3274
Study 38753452 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of direct oral anticoagulants
Number of subjects: 1970
Study 38753528 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical enhancement mode 2
Number of subjects: 2430
Study 38753528 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 2430
Study 38753616 — intervention group
Group type: EXPERIMENTAL
Intervention: Close Assessment and Testing for Chronic GVHD (CATCH) study intervention including clinician assessment, patient-reported outcomes, and multiple biospecimens collection.
Number of subjects: 0
Study 38753757 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical therapy using alpha emitters
Number of subjects: 0
Study 38753757 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel targets such as tumor-specific antigens, overexpressed receptors, and intracellular biomolecules
Number of subjects: 0
Study 38753757 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha emitters
Number of subjects: 0
Study 38753764 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote live stream assessment of the North Star Ambulatory Assessment
Number of subjects: 0
Study 38753764 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment of the North Star Ambulatory Assessment
Number of subjects: 0
Study 38753813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 1319
Study 38753813 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 1319
Study 38753813 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP) + single-dose azithromycin (AZ)
Number of subjects: 1319
Study 38753869 — intervention group
Group type: EXPERIMENTAL
Intervention: High load (standing with weight vest weighing 11% of body weight)
Number of subjects: 10
Study 38753869 — intervention group
Group type: COMPARATOR
Intervention: No load (sitting)
Number of subjects: 10
Study 38754046 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 77
Study 38754046 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 77
Study 38754056 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (200 or 300 mg once daily), Dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), Bevacizumab (15 mg/kg once every 3 weeks)
Number of subjects: 41
Study 38754056 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib, Dostarlimab, and Bevacizumab
Number of subjects: 41
Study 38754068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred monitoring (PCM)
Number of subjects: 187
Study 38754068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (dolutegravir plus emtricitabine)
Number of subjects: 187
Study 38754068 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 187
Study 38754068 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 187
Study 38754068 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring options
Number of subjects: 187
Study 38754068 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function, lipids, glucose values, weight
Number of subjects: 187
Study 38754101 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychological intervention incorporating cognitive behavioral therapy tools, diabetes self-care promotion, and mindfulness
Number of subjects: 49
Study 38754101 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 49
Study 38754125 — intervention group
Group type: EXPERIMENTAL
Intervention: bimekizumab 160 mg every 4 weeks
Number of subjects: 1112
Study 38754125 — intervention group
Group type: COMPARATOR
Intervention: placebo/bimekizumab
Number of subjects: 1112
Study 38754125 — intervention group
Group type: EXPERIMENTAL
Intervention: bimekizumab
Number of subjects: 1112
Study 38754454 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) initiated before clinical stabilisation
Number of subjects: 2221
Study 38754454 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 2221
Study 38754459 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg daily for 6 weeks
Number of subjects: 240
Study 38754459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 38754466 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic full-thickness resection (EFTR) using the full-thickness resection device (FTRD)
Number of subjects: 750
Study 38754593 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of electrospun poly (L-lactide-co-caprolactone) and formulated porcine fibrinogen (PLCL/Fg) dressing
Number of subjects: 0
Study 38754593 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 0
Study 38754780 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant dabrafenib 150 mg (orally twice per day) plus trametinib 2 mg (orally once per day) for 52 weeks
Number of subjects: 35
Study 38754780 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological complete response (pCR)
Number of subjects: 35
Study 38754874 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cTBS group
Number of subjects: 60
Study 38754874 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS group
Number of subjects: 60
Study 38754878 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D reconstruction automated matching system (3DRACS) for DLT size selection
Number of subjects: 200
Study 38754878 — intervention group
Group type: COMPARATOR
Intervention: Blind DLT intubation method based on height and sex (Control)
Number of subjects: 200
Study 38754876 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors assessed at 1-month post-surgery for subjective UL function (QuickDASH) at 6 months post-cancer treatment.
Number of subjects: 250